文献速递帕金森病与运动障碍

PRKN基因替代翻译起始延缓帕金森病发病并提供治疗靶点

Alternative Translation Initiation in PRKN Delays the Onset of Parkinson's Disease and Offers a Therapeutic Target.
PubMed 文献 · Ann Neurol · 2026-02-22

该研究比较26例PRKN外显子2纯合缺失携带者与其他致病变异携带者的发病年龄,并利用患者来源iPSC神经元等模型探索机制。结果显示外显子2缺失者发病较晚,与内部翻译起始产生的N端截短Parkin蛋白保留部分泛素连接酶活性有关;调节剂BIO-2007817可增强该残余功能但抑制内源性全长Parkin活性。

要点

  • PRKN外显子2纯合缺失携带者发病年龄晚于其他致病变异携带者。
  • 截短Parkin蛋白由内部翻译起始产生,保留部分泛素连接酶活性。
  • BIO-2007817增强截短Parkin功能但抑制全长Parkin,需按基因型分层。

核心结论

  • 截短Parkin的残余功能可解释PRKN外显子2缺失携带者发病延迟,并可能成为突变特异性治疗靶点。

研究设计与样本

  • 比较26例PRKN外显子2纯合缺失携带者与其他致病变异携带者的发病年龄。
  • 利用86岁未发病携带者来源的hiPSC神经元、基因编辑对照细胞、神经母细胞瘤细胞系及计算机预测研究机制。

主要发现

  • PRKN外显子2缺失患者发病年龄晚于其他致病变异携带者。
  • 发现因内部翻译起始产生的缺失氨基酸1-79的N端截短Parkin蛋白水平升高。
  • 该截短蛋白在内源性水平部分保留泛素连接酶活性。
  • BIO-2007817增强截短Parkin残余功能,但降低内源性全长Parkin活性。

关键数值与推荐

  • PRKN双等位基因变异所致常染色体隐性帕金森病中位发病年龄为31岁。
  • MDSGene数据库中16例PRKN外显子2纯合缺失携带者中位发病年龄为39.5岁,晚于其他PRKN致病变异携带者。

临床怎么用

  • 对PRKN外显子2缺失携带者可提供突变特异性遗传咨询,提示发病可能较晚。
  • 若使用Parkin调节剂,需基于基因型严格分层,避免抑制全长Parkin带来的不利影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Biallelic variants in PRKN cause autosomal recessive Parkinson's disease (PD) with a median age at onset of 31 years. When evaluating the 16 previously published carriers of a homozygous deletion of Exon 2 from the International Parkinson's Disease and Movement Disorder Society Gene Database (MDSGene) database, the median age at onset is later (39.5 years) than in carriers of other PRKN pathogenic variants. We investigated whether these carriers show delayed disease onset compared with carriers of other pathogenic PRKN variants and explored the underlying molecular mechanism. METHODS: We compared 26 homozygous PRKN Exon 2 deletion carriers with carriers of other pathogenic variants. Using human-induced pluripotent stem cell (hiPSC)-derived neuronal cell models from an unaffected 86-year-old carrier, genome-edited control lines, neuroblastoma cell lines, and in silico prediction, we investigated the underlying mechanism. RESULTS: Patients with PRKN Exon 2 deletions showed a later age at onset compared with carriers of other pathogenic variants. We discovered elevated levels of an N-terminally truncated Parkin proteoform lacking amino acids 1-79 due to internal translation initiation. This truncated protein partially retained ubiquitin ligase activity at endogenous levels. Treatment with Parkin modulator BIO-2007817 enhanced this residual function but reduced endogenous full-length Parkin activity. INTERPRETATION: Residual truncated Parkin function provides a molecular explanation for a delayed disease onset in PRKN Exon 2 deletion carriers. Whereas this retained activity can be pharmacologically enhanced, the modulator's inhibitory effect on endogenous full-length Parkin may mandate strict patient stratification based on genotype. This finding offers mutation-specific counseling opportunities and highlights a potential therapeutic approach for appropriately selected patients with PARK-PRKN. ANN NEUROL 2026;99:1379-1393.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Hach A, Lohmann K, Funayama M, et al. Alternative Translation Initiation in PRKN Delays the Onset of Parkinson's Disease and Offers a Therapeutic Target. Ann Neurol. 2026. PMID: 41724727. doi:10.1002/ana.78180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。